PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. ALIMERA SCIENCES LIMITED
AS

ALIMERA SCIENCES LIMITED

Hook
SME

Alimera Sciences Limited is a pharmaceutical company dedicated to developing innovative treatments for chronic retinal diseases. Their mission is to improve vision for patients through collaboration with the medical community.

alimerasciences.co.uk ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£688.8m
Live
3
Buyers
2
12m
£688.8m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts3 / 4
  • Top buyers2
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags1
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — ALIMERA SCIENCES LIMITEDUpdated 06 Jul 2026

At a glance · for buyers and watchdogs

ALIMERA SCIENCES LIMITED has won £688.8m across 2 public-sector buyers, with 3 live contracts.

Why: top buyer NHS England North East and Yorkshire Health and Justice at 100% · 1 active risk flag · 0 modifications.

Decision signals
1Active red flags
ActiveCompany status
3 of 4Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 1
Product DevelopmentDevelopment of innovative treatments for retinal diseases. ↗

Extracted automatically from alimerasciences.co.uk on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 3 live · 1 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England North East and Yorkshire Health and Justice—01 Dec 2025£688.8m1.5 yrspending
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England————Live
NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024
NHS England33600000———Live
NHS Framework Agreement for the supply of Medical Retinal Vascular Treatments
NHS England33690000———Live
Total live value — · mean award £172.2m

Top buyers · 2 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England North East and Yorkshire Health and Justice
1 contract
100%
since 2025
2
NHS England
3 contracts
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire4 contracts
100%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). ALIMERA SCIENCES LIMITED highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
AS
ALIMERA SCIENCES LIMITED
Yes£688.8m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 1 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
Confirmation statement overdue. Statement was due 17 Apr 2026.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Overdue
Due 17 Apr 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
08018355
Status
Active
Type
Private limited
Incorporated
03 Apr 2012
Reg. office
Form 1 Bartley Wood Business Park, Hook, Hampshire, RG27 9XA
SIC codes
82990
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • CSC CLS (UK) LIMITED — corporate secretary
    Appointed 30 Jan 2026
  • CAREY, Stephen Philip — director
    Appointed 12 Dec 2024
  • LALWANI, Nikhil — director
    Appointed 12 Dec 2024
  • ASHMAN, Philip John — director
    Appointed 01 Jan 2013
  • Ani Pharmaceuticals, Inc. — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
ALIMERA SCIENCES LIMITED
08018355 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.